Erectile dysfunction not linked to RA, rather warrants a low CV risk, claims study

Written By :  Dr Satabdi Saha
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-08-02 04:30 GMT   |   Update On 2021-08-02 04:29 GMT
Advertisement

Researchers have highlighted that the incidence of erectile dysfunction was not statistically increased in rheumatoid arthritis, further elaborating that although patients with both RA and ED had a similar overall CV risk to those with RA alone, men with both RA and ED had decreased risk of heart failure, myocardial infarction, and death, as well as an increased risk of peripheral arterial disease.

Advertisement

The findings have been put forth in Journal of Rheumatology.

Both erectile dysfunction (ED) and rheumatoid arthritis (RA) are associated with increased cardiovascular (CV) risk. Many epidemiologic studies have investigated the link between ED and risk of CVD, and most found a positive association. However, the magnitudes of the association varied between studies. It is unknown if these diagnoses are associated or if their combination confers additional CV risk. We aimed to define the incidence of ED in RA, and to determine if ED correlates with increased CV risk in RA.

The data for the study concisted of Medical information concerning RA, ED, and CV diagnoses for men with RA (n = 260) diagnosed in Olmsted County, Minnesota, and age-matched male comparators was extracted from a comprehensive medical record system.

Results put forth some interesting facts.

  • ED incidence was similar between the RA cohort and comparators (HR 0.80, 95% CI 0.55–1.16).
  • In men with RA, ED diagnosis was associated with a trend toward an increase in peripheral arterial disease (HR 2.22, 95% CI 0.98–5.03) and a significantly decreased rate of myocardial infarction (HR 0.26, 95% CI 0.07–0.90), heart failure (HR 0.49, 95% CI 0.25–0.94), and death (HR 0.56; 95% CI 0.36–0.87).
  • In men with RA and ED, phosphodiesterase-5 inhibitor use was associated with a decreased risk of death (HR 0.35, 95% CI 0.16–0.79), with a trending decreased risk of some CV diagnoses.

"Further studies are needed to clarify these associations and their implications for pathogenesis and therapeutics." The team opined.

For full article follow the link: DOI: 10.3899/jrheum.201226


Source: Journal of Rheumatology

Tags:    
Article Source : Journal of Rheumatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News